CliffBio
small molecule

LIVMARLI

MARALIXIBAT CHLORIDE

Loss of exclusivityOctober 2032latest FDA-listed patent expiry
CompanyMirum Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameLIVMARLI
Active ingredientMARALIXIBAT CHLORIDE
StrengthEQ 19MG BASE/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2024
Marketing statusRX

Listed patents

PatentExpiresType
12350267October 2032use U-3973
11229661October 2032use U-3973
10512657October 2032use U-3973

Regulatory exclusivity

CodeExpires
ODE-490July 2031
ODE*March 2031
ODE*March 2030
ODE*September 2028
NCESeptember 2026

More from Mirum Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LIVMARLI patent cliff — loss of exclusivity October 2032 | CliffBio